

## Disclosures

### Personal Commercial (14)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Acasti	Research/Research Grants	Significant (>= \$5,000)	<i>Prevention</i>
Amgen	Research/Research Grants ‡ <i>VESELIUS</i>	Significant (>= \$5,000)	<i>Prevention</i>
Astra Zeneca	Research/Research Grants ‡ <i>STRENGTH</i>	Significant (>= \$5,000)	<i>Prevention</i>
Eli Lilly and Company	Research/Research Grants ‡ <i>GPGN, GPGL</i>	Significant (>= \$5,000)	<i>Prevention</i>
Esperion	Research/Research Grants ‡ <i>CLEAR OUTCOMES</i>	Significant (>= \$5,000)	<i>Prevention</i>
Getz Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Medicines Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Medicines Company	Research/Research Grants ‡ <i>ORION-4</i>	Significant (>= \$5,000)	<i>Prevention</i>
Novartis	Research/Research Grants ‡ <i>HERITAGE, HORIZON</i>	Significant (>= \$5,000)	<i>Prevention</i>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Novo-Nordisk	Research/Research Grants ‡ <i>SELECT</i>	Significant (>= \$5,000)	<i>Prevention</i>
Pfizer Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Regeneron	Research/Research Grants ‡ <i>ODYSSEY</i>	Significant (>= \$5,000)	<i>Prevention</i>
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	<i>Prevention</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/13/2021

 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>
**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/11/2021

**Embargo** | Signed on 10/13/2021

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 10/13/2021

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.